BMRN
Price
$57.54
Change
-$0.46 (-0.79%)
Updated
Aug 15 closing price
Capitalization
11.05B
65 days until earnings call
DNTH
Price
$20.74
Change
+$0.49 (+2.42%)
Updated
Aug 15 closing price
Capitalization
667.59M
Interact to see
Advertisement

BMRN vs DNTH

Header iconBMRN vs DNTH Comparison
Open Charts BMRN vs DNTHBanner chart's image
BioMarin Pharmaceutical
Price$57.54
Change-$0.46 (-0.79%)
Volume$2.53M
Capitalization11.05B
Dianthus Therapeutics
Price$20.74
Change+$0.49 (+2.42%)
Volume$280.14K
Capitalization667.59M
BMRN vs DNTH Comparison Chart in %
Loading...
BMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMRN vs. DNTH commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a Hold and DNTH is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (BMRN: $57.54 vs. DNTH: $20.74)
Brand notoriety: BMRN and DNTH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BMRN: 120% vs. DNTH: 82%
Market capitalization -- BMRN: $11.05B vs. DNTH: $667.59M
BMRN [@Biotechnology] is valued at $11.05B. DNTH’s [@Biotechnology] market capitalization is $667.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMRN’s FA Score shows that 0 FA rating(s) are green whileDNTH’s FA Score has 0 green FA rating(s).

  • BMRN’s FA Score: 0 green, 5 red.
  • DNTH’s FA Score: 0 green, 5 red.
According to our system of comparison, DNTH is a better buy in the long-term than BMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMRN’s TA Score shows that 5 TA indicator(s) are bullish while DNTH’s TA Score has 5 bullish TA indicator(s).

  • BMRN’s TA Score: 5 bullish, 4 bearish.
  • DNTH’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, DNTH is a better buy in the short-term than BMRN.

Price Growth

BMRN (@Biotechnology) experienced а -3.23% price change this week, while DNTH (@Biotechnology) price change was +10.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.94%. For the same industry, the average monthly price growth was +21.39%, and the average quarterly price growth was +21.23%.

Reported Earning Dates

BMRN is expected to report earnings on Oct 22, 2025.

Industries' Descriptions

@Biotechnology (+5.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BMRN($11B) has a higher market cap than DNTH($668M). BMRN has higher P/E ratio than DNTH: BMRN (16.97) vs DNTH (3.24). DNTH YTD gains are higher at: -4.862 vs. BMRN (-12.460). BMRN has higher annual earnings (EBITDA): 777M vs. DNTH (-116.76M). BMRN has more cash in the bank: 1.27B vs. DNTH (263M). DNTH has less debt than BMRN: DNTH (1.4M) vs BMRN (602M). BMRN has higher revenues than DNTH: BMRN (2.95B) vs DNTH (6.52M).
BMRNDNTHBMRN / DNTH
Capitalization11B668M1,647%
EBITDA777M-116.76M-665%
Gain YTD-12.460-4.862256%
P/E Ratio16.973.24524%
Revenue2.95B6.52M45,218%
Total Cash1.27B263M484%
Total Debt602M1.4M43,123%
FUNDAMENTALS RATINGS
BMRN vs DNTH: Fundamental Ratings
BMRN
DNTH
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
10054
SMR RATING
1..100
7196
PRICE GROWTH RATING
1..100
7760
P/E GROWTH RATING
1..100
9966
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNTH's Valuation (53) in the null industry is in the same range as BMRN (56) in the Biotechnology industry. This means that DNTH’s stock grew similarly to BMRN’s over the last 12 months.

DNTH's Profit vs Risk Rating (54) in the null industry is somewhat better than the same rating for BMRN (100) in the Biotechnology industry. This means that DNTH’s stock grew somewhat faster than BMRN’s over the last 12 months.

BMRN's SMR Rating (71) in the Biotechnology industry is in the same range as DNTH (96) in the null industry. This means that BMRN’s stock grew similarly to DNTH’s over the last 12 months.

DNTH's Price Growth Rating (60) in the null industry is in the same range as BMRN (77) in the Biotechnology industry. This means that DNTH’s stock grew similarly to BMRN’s over the last 12 months.

DNTH's P/E Growth Rating (66) in the null industry is somewhat better than the same rating for BMRN (99) in the Biotechnology industry. This means that DNTH’s stock grew somewhat faster than BMRN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMRNDNTH
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
64%
Bullish Trend 4 days ago
84%
Momentum
ODDS (%)
Bearish Trend 4 days ago
72%
Bullish Trend 4 days ago
87%
MACD
ODDS (%)
Bearish Trend 4 days ago
72%
Bearish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
64%
Bullish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
61%
Bullish Trend 4 days ago
79%
Advances
ODDS (%)
Bullish Trend 6 days ago
60%
Bullish Trend 6 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
62%
Bearish Trend 11 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
68%
Bullish Trend 4 days ago
81%
Aroon
ODDS (%)
Bullish Trend 4 days ago
47%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EZJ49.251.61
+3.39%
ProShares Ultra MSCI Japan
ECAT16.69N/A
N/A
BlackRock ESG Capital Allocation Term Trust
TCPB50.85-0.12
-0.23%
Thrivent Core Plus Bond ETF
NPCT10.96-0.07
-0.63%
Nuveen Core Plus Impact Fund
SLX69.57-0.48
-0.69%
VanEck Steel ETF

BMRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMRN has been loosely correlated with ITOS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if BMRN jumps, then ITOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMRN
1D Price
Change %
BMRN100%
-0.79%
ITOS - BMRN
50%
Loosely correlated
N/A
IBO - BMRN
42%
Loosely correlated
+1.66%
IONS - BMRN
42%
Loosely correlated
+2.17%
DNTH - BMRN
40%
Loosely correlated
+2.42%
IDYA - BMRN
40%
Loosely correlated
-0.16%
More

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with IMNM. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
+2.42%
IMNM - DNTH
56%
Loosely correlated
+3.42%
XNCR - DNTH
53%
Loosely correlated
+0.39%
OCUL - DNTH
50%
Loosely correlated
-0.24%
ERAS - DNTH
49%
Loosely correlated
+4.46%
SYRE - DNTH
49%
Loosely correlated
+0.53%
More